ICON Wins Best Poster Award at ISPOR 2009


Dublin, Ireland, November 13th, 2009 – ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Best Poster Presentation award at the ISPOR 12th Annual European Congress, which took place in Paris from 6 – 9th November, 2009.

The paper, entitled Reducing Bias In A Retrospective Case-Control Study: An Application of Propensity Score Matching was co-authored by Alex Exuzides, Director Statistical Analysis, ICON Clinical Research; and Chris Colby, Research Scientist ICON Clinical Research and Jonathan Goldman, Chief Medical Officer, ICON Medical Imaging.

To view the poster, click here

The ISPOR Best Research Podium and Poster Presentation Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, and Asia-Pacific Conferences. At this year's European Congress, the ISPOR Awards Committee evaluated 75 podium presentations and over 1,000 poster presentations.

Evaluations of scientific merit were based upon the following criteria: 

  • Background provides appropriate perspective/context for the subject 
  • Objectives / research questions are clearly stated 
  • Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties) 
  • Data sources and/or sampling procedures are clear and appropriate 
  • Data analyses are appropriate 
  • Research objectives are met/addressed 
  • Implications of findings are discussed 
  • Factual information is kept separate from interpretations or implications 
  • Abstract is presented in an unbiased manner 
  • Clarity of presentation

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,000 employees, operating from 68 locations in 38 countries.